Three new IPO filings broaden fall queue

A trio of biotechs filed for NASDAQ listings late Monday, with Phathom, 4D Molecular Therapeutics and Cabaletta each proposing to raise up to $100 million. A fourth, Vir, set terms for an IPO that could price as soon as this week.

The filings fatten a queue that is growing again following a late-summer lull. “We’re seeing more IPOs,” WBB Securities' Steve Brozak told BioCentury. “People are now rushing to get money” (see “Fall IPO Flurry”)...